24 Facts About Illumina Inc

Illumina Inc provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets.

Illumina Inc was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.

In 1999, Illumina Inc acquired Spyder Instruments for their technology of high-throughput synthesis.

Illumina Inc began offering single nucleotide polymorphism genotyping services in 2001 and launched its first system, the Illumina Inc BeadLab, in 2002, using GoldenGate Genotyping technology.

Illumina Inc's technologies are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

Related searches

Illumina Inc uses the DNA colony sequencing technology, invented in 1997 by Pascal Mayer and Laurent Farinelli and which was acquired by Solexa in 2004 from the company Manteia Predictive Medicine.

In June 2009, Illumina Inc announced the launch of their own Personal Full Genome Sequencing Service at a depth of 30X for $48,000 per genome, and a year later dropped the price to $19,500.

Until 2010, Illumina Inc sold only instruments that were labeled "for research use only"; in early 2010, Illumina Inc obtained FDA approval for its BeadXpress system to be used in clinical tests.

Illumina Inc acquired Epicentre Biotechnologies, based in Madison, Wisconsin, on January 11,2011.

Illumina Inc claimed that 40 such machines would be able to sequence more genomes in one year than had been produced by all other sequencers to date.

In late 2015, Illumina Inc spun off the company GRAIL, focused on blood testing for cancer tumors in the bloodstream.

In September 2020, Illumina Inc announced a proposed cash and stock deal to acquire Grail for $8 billion.

Illumina Inc sells a number of high-throughput DNA sequencing systems, known as DNA sequencers, based on technology developed by Solexa.

Illumina Inc sequencers are highly accurate, and only have an error once every thousand bases.

In 2010, Cornell University and Life Technologies filed a lawsuit against Illumina Inc, alleging that its microarray products infringed on eight patents held by the university and exclusively licensed to the start-up.

Cornell claimed that ThermoFisher had promised to settle the suit with Illumina Inc and asked for the Markman wording to be dropped so that it could file a subsequent suit involving other patents invented at Cornell.

William Noon, an in-house attorney at Illumina Inc, had filed a FOIA request for 4 of these key grants as well in January 2015.

Illumina Inc was a party in a patent lawsuit against competitor Ariosa Diagnostics.

In February 2016, Illumina Inc filed a lawsuit against Oxford Nanopore Technologies.

Illumina Inc claimed that Oxford Nanopore infringed its patents on the use of a biological nanopore, Mycobacterium smegmatis porinA, for sequencing systems.

In February 2020, Illumina Inc filed a patent infringement suit against BGI relating to its "CoolMPS" sequencing products.

However, in May 2022, Illumina Inc was ordered to pay $333 million to a US unit of BGI in California for infringing two patents of DNA-sequencing systems.

The jury of the case said that Illumina Inc willfully infringed the patents, and that their former accusation of BGI's infringement was invalid.

On May 6,2022, a jury in the US District Court for the District of Delaware rendered a verdict that Illumina Inc willfully infringed two patents owned by Complete Genomics, and awarded approximately $334 million to CGI in past damages.